Integrative Multi-omics Analysis Reveals Different Metabolic Phenotypes Based on Molecular Characteristics in Thyroid Cancer
- 13 December 2023
- journal article
- research article
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 30 (4) , 883-894
Abstract
Purpose: Thyroid cancer metabolic characteristics vary depending on the molecular subtype determined by mutational status. We aimed to investigate the molecular subtype-specific metabolic characteristics of thyroid cancers. Experimental Design: An integrative multi-omics analysis was conducted, incorporating transcriptomics, metabolomics, and proteomics data obtained from human tissues representing distinct molecular characteristics of thyroid cancers: BRAF-like (papillary thyroid cancer with BRAFV600E mutation; PTC-B), RAS-like (follicular thyroid cancer with RAS mutation; FTC-R), and ATC-like (anaplastic thyroid cancer with BRAFV600E or RAS mutation; ATC-B or ATC-R). To validate our findings, we employed tissue microarray of human thyroid cancer tissues and performed in vitro analyses of cancer cell phenotypes and metabolomic assays after inducing genetic knockdown. Results: Metabolic properties differed between differentiated thyroid cancers of PTC-B and FTC-R, but were similar in dedifferentiated thyroid cancers of ATC-B/R, regardless of their mutational status. Tricarboxylic acid (TCA) intermediates and branched-chain amino acids (BCAA) were enriched with the activation of TCA cycle only in FTC-R, whereas one-carbon metabolism and pyrimidine metabolism increased in both PTC-B and FTC-R and to a great extent in ATC-B/R. However, the protein expression levels of the BCAA transporter (SLC7A5) and a key enzyme in one-carbon metabolism (SHMT2) increased in all thyroid cancers and were particularly high in ATC-B/R. Knockdown of SLC7A5 or SHMT2 inhibited the migration and proliferation of thyroid cancer cell lines differently, depending on the mutational status. Conclusions: These findings define the metabolic properties of each molecular subtype of thyroid cancers and identify metabolic vulnerabilities, providing a rationale for therapies targeting its altered metabolic pathways in advanced thyroid cancer.Keywords
All Related Versions
Funding Information
- National Research Foundation of Korea (NRF-2018R1A5A2024425)
- National Research Foundation of Korea (NRF-2019R1A2C2084332)
- National Research Foundation of Korea (NRF-2021R1I1A4A01057387)
- National Research Foundation of Korea (5120200513755)
This publication has 51 references indexed in Scilit:
- The hallmarks of cancer metabolism: Still emergingCell Metabolism, 2022
- Emerging Roles for Branched-Chain Amino Acid Metabolism in CancerCancer Cell, 2020
- Advances in metabolomics of thyroid cancer diagnosis and metabolic regulationEndocrine, 2019
- Targeting glutaminase-mediated glutamine dependence in papillary thyroid cancerJournal of Molecular Medicine, 2018
- Multicompartment metabolism in papillary thyroid cancerThe Laryngoscope, 2015
- Integrated Genomic Characterization of Papillary Thyroid CarcinomaCell, 2014
- Expression Patterns of Glucose Transporter-1 Gene and Thyroid Specific Genes in Human Papillary Thyroid CarcinomaNuclear Medicine and Molecular Imaging, 2014
- Influence of Metabolism on Epigenetics and DiseaseCell, 2013
- Cell-specific expression and immunolocalization of nitric oxide synthase isoforms and soluble guanylyl cyclase α1 and β1 subunits in the ovary of fetal, neonatal and immature pigsAnimal Reproduction Science, 2012
- Hallmarks of Cancer: The Next GenerationCell, 2011